Efficacy and safety of lapatinib in Chinese breast cancer patients: a real-world study

BACKGROUND: Lapatinib is approved for the treatment of metastatic HER2-overexpressed breast cancer with capecitabine after progress on anthracycline, taxane, and trastuzumab in China. A post-marketing pharmacovigilance program was carried out to verify the real-world safety and the efficacy informat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Xuan, Luo, Xin, Du, Qiong, Li, Huan, Liu, Hong-Yue, Yu, Bo, Zhai, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154472/
https://www.ncbi.nlm.nih.gov/pubmed/32309387
http://dx.doi.org/10.21037/atm.2020.03.21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154472/
https://www.ncbi.nlm.nih.gov/pubmed/32309387
http://dx.doi.org/10.21037/atm.2020.03.21

Ejemplares similares